THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 123 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 3.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,965,580 | -10.1% | 459,511 | +7.8% | 0.00% | 0.0% |
| Q2 2023 | $4,413,447 | +231.3% | 426,420 | +247.3% | 0.00% | 0.0% |
| Q1 2023 | $1,332,011 | -18.8% | 122,766 | -16.0% | 0.00% | 0.0% |
| Q4 2022 | $1,639,848 | -14.9% | 146,154 | -23.1% | 0.00% | 0.0% |
| Q3 2022 | $1,926,000 | +145.0% | 189,947 | +119.0% | 0.00% | – |
| Q2 2022 | $786,000 | -82.8% | 86,733 | -81.8% | 0.00% | -100.0% |
| Q1 2022 | $4,565,000 | +675.0% | 477,434 | +796.3% | 0.00% | – |
| Q4 2021 | $589,000 | +450.5% | 53,266 | +268.7% | 0.00% | – |
| Q3 2021 | $107,000 | -63.1% | 14,446 | +1.8% | 0.00% | – |
| Q1 2021 | $290,000 | -7.3% | 14,192 | -32.9% | 0.00% | – |
| Q3 2020 | $313,000 | -98.8% | 21,140 | -98.3% | 0.00% | -100.0% |
| Q2 2020 | $25,585,000 | +646.6% | 1,218,912 | +762.5% | 0.02% | +111.1% |
| Q1 2018 | $3,427,000 | +1622.1% | 141,329 | +1235.3% | 0.01% | +800.0% |
| Q1 2016 | $199,000 | – | 10,584 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |